BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...

Noridian latest MAC to make Elucid PlaqueIQTM image analysis software available for eligible patients BOSTON – October 25, 2024 – Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared...

New policy to make company’s PlaqueIQTM image analysis software available to eligible patients with suspected coronary artery disease BOSTON – October 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend...

Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular risk BOSTON, Nov. 9, 2023 – Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to...

BOSTON, Sept. 6, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Windi Hary as senior vice president (SVP) of regulatory affairs and quality...

BOSTON, April 25, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of...

BOSTON, March 28, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead...

Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago.

Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago.

Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.